Navigation Links
Developing Robust Potency Assays for Validation, New Webinar hosted by Xtalks
Date:1/30/2013

Toronto, Canada (PRWEB) January 30, 2013

Cell-based assays, or bioassays, are important for establishing safety, efficacy and stability profiles biopharmaceuticals. What’s more, these assays must be sufficiently robust to meet international regulatory and USP guidelines for system suitability. These tools are crucial for drug product lot release and stability testing to support licensing for commercialization.

Generally, assays are designed to demonstrate the relative potency of a product by comparing the biological response with a control preparation (such as USP, WHO, or an in-house reference standard). These assays are an essential component of the characterization/validation process and can be used to select candidates; establish comparability; test process intermediates, formulations and stability/degradation; and to support product changes.

In this webinar, our expert, Dr. Peter Wunderli, will review a case study for a biological drug product. Dr. Wunderli will go over topics including: the re-development of the bioassay method for potency and an improved process for extracting the drug product from a carrier so that the potency of the final drug product could be reproducibly measured.

For more information about this event or to register, visit: http://xtks.in/xto561-event

Xtalks is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10375843.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Gated STED -- developing the next generation of super-resolution microscopes
2. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
3. Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market
4. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
5. SRI International Researchers Developing Bioadhesive Gel to Protect Women from HIV and HSV Infections
6. Carnegie Mellons Jeffrey Hollinger Leads Research Team Developing New Tools To Ease Pain of Combat Injuries
7. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
8. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
9. endpoint Adopts New Technology To Boast Most Robust IVR Validation Objective Evidence and Decrease IVR Build Timelines
10. New nanotech fiber: Robust handling, shocking performance
11. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... -- On Thursday, March 23, 2017, the ... 0.07%; the Dow Jones Industrial Average edged 0.02% lower, ... at 2,345.96, marginally dropping 0.11%. US markets saw a ... sectors finished in red, and 1 sector ended flat ... coverage on the following Biotechnology equities: BioDelivery Sciences International ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed ... both viscous and elastic characteristics when deformed, which is identical to how the ... gently absorb compressive forces and return to its natural state along a hysteresis ...
(Date:3/23/2017)... March 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) ... immune therapies for solid tumor cancers, today announced ... financing it announced last Friday, March 17, 2017. ... institutional investors securities totaling 28,843,692 shares, comprised of ... 10,000,000 shares of Class C Warrants pre-funded at ...
Breaking Biology Technology:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):